Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy

NCT07332143
Conditions
PTSD
Interventions
psilocybin, Supportive Therapy, Prolonged Exposure Therapy
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Anna Rose Childress, Ph.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Binge Eating Disorder
Interventions
TRYP-0082, Psychotherapy
Drug · Behavioral
Lead sponsor
TRYP Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Major Depression
Interventions
Psilocybin (Usona Institute), Propofol, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
25 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Recruiting Phase 1 Interventional Accepts healthy volunteers

The ENHANCE Study: taVNS and Psilocybin

NCT05866471
Conditions
Healthy, Psychedelic Experiences, Vagus Nerve Stimulation
Interventions
Psilocybin, Transcutaneous auricular Vagus Nerve Stimulation (taVNS), Psychosocial Support Alone, Sham taVNS
Drug · Device · Behavioral + 1 more
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Borderline Personality Disorder, Borderline Personality Pathology, Depressive Symptoms, Emotion Dysregulation, Suicidal Ideation
Interventions
Psilocybin, Psilocybin-Assisted Therapy With Dialectical Behavior Therapy
Drug · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
25 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Louis Park, Minnesota
Conditions
Depression, Anxiety, Psilocybin-Assisted Psychotherapy, Advanced Cancer
Interventions
Psilocybin, Niacin
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Persisting Effects of Psilocybin

NCT02971605
Conditions
Healthy
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Visual Surround Suppression and Perceptual Expectation Under Psilocybin

NCT04424225
Conditions
Perception Disturbance, Visual Suppression, Psychedelic Experiences
Interventions
Psilocybin, Niacin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
25 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Healthy Participants With Lower-than-average Mental Well-being
Interventions
Psilocybin, Context 1, Context 2, Placebo
Drug · Behavioral
Lead sponsor
Robin Carhart-Harris, PhD, MA
Other
Eligibility
21 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Chronic Low-back Pain, Depression
Interventions
Psilocybin, Methylphenidate
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Cancer, Major Depressive Disorder
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Sunstone Medical
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rockville, Maryland
Conditions
Methamphetamine Use Disorder, Substance-Related Disorders, Chemically-Induced Disorders, Substance Use Disorders, Stimulant-Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
25 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Active, not recruiting Phase 1 Interventional

Effects of Repeated Psilocybin Dosing in OCD

NCT05370911
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut
Conditions
Depression
Interventions
Psilocybin (Usona Institute)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Post Traumatic Stress Disorder
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Rockville, Maryland • New York, New York
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Neural and Physiological Correlates of Psychedelic Sub-states

NCT05698511
Conditions
Psychedelic Experiences, Neuroimaging, Healthy Volunteers
Interventions
Psilocybin
Drug
Lead sponsor
Robin Carhart-Harris, PhD, MA
Other
Eligibility
21 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Alcohol Dependence
Interventions
Psilocybin, Diphenhydramine, Motivational Enhancement and Taking Action (META)
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
25 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Albuquerque, New Mexico • New York, New York
Active, not recruiting Phase 1 Interventional

A Study of Psilocybin for PTSD

NCT06407635
Conditions
Post Traumatic Stress Disorder
Interventions
Psilocybin, Trauma-focused psychotherapy, Standard psychological support
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Anorexia Nervosa
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
San Diego, California • Baltimore, Maryland • Austin, Texas
Conditions
Alcohol Use Disorder
Interventions
Psilocybin, Inactive Placebo, Supportive therapy sessions
Drug · Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Conditions
Depressive Symptoms, Depression, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Body Dysmorphic Disorders
Interventions
Psilocybin
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Psilocybin for Prolonged Grief Disorder

NCT06724289
Conditions
Prolonged Grief Disorder
Interventions
Psilocybin 25 mg, Functional Magnetic Resonance Imaging (fMRI)
Drug · Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia